RamYogevMD

Pediatric Infectious Disease • Chicago, IL

Professor Emeritus , Northwestern University Medical School

Join to view full profile

Dr. Yogev is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Yogev's full profile

Already have an account?

Office
2300 Childrens Plaza
Chicago, IL 60614
Phone+1 773-880-4757

Fax+1 773-880-3208

Education & Training

McGaw Medical Center of Northwestern UniversityResidency, Pediatrics, 1975 - 1976
The Hebrew University of Jerusalem Hadassah Medical SchoolClass of 1969

Certifications & Licensure

IL State Medical License 1977 - 2026
American Board of Pediatrics Pediatrics

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Fellow (FAAP) American Academy of Pediatrics

Clinical Trials

A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in Infants and Children With Documented HIV-1 Infection
Completed
Phase 1
A Study to Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive Children
Completed
Phase 2
The Safety and Effects of 1592U89 Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Infants and Children
Completed
Phase 1
A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and Children
Completed
Phase 1
The Safety of Zidovudine Plus Interferon-Alpha in HIV-Infected Children
Completed
Phase 1
A Study on the Rate of Opportunistic (AIDS-Related) Infections Among HIV-Positive Children Who Have Stopped Taking Their OI Preventive Medications
Completed
Not Applicable
Ritonavir and Indinavir in Children Failing Other Anti-HIV Treatment
Completed
Phase 1, Phase 2
Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children Start of enrollment: 2006 Feb 01
Completed
Phase 1, Phase 2
Safety and Tolerability of a Therapeutic DNA Dendritic Cell Vaccine in HIV-Infected Children, Adolescents, and Young Adults
Withdrawn
Phase 1, Phase 2
Safety and Pharmacokinetic Study of Fixed Dose Combination of Zidovudine, Lamivudine, and Nevirapine in HIV-Infected Children in Thailand Start of enrollment: 2008 Oct 01
Completed
Phase 1, Phase 2
IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults Start of enrollment: 2002 Aug 01
Completed
IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents Start of enrollment: 2010 Oct 08
Completed
Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women Start of enrollment: 2007 Mar 01
Recruiting
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care Start of enrollment: 2011 Nov 01
Completed
Adolescent Master Protocol for Participants 18 Years of Age and Older (AMP Up) Start of enrollment: 2014 Apr 01
Recruiting
Join now to see all

Publications & Presentations

PubMed

37 citations
Live-attenuated Vaccines Prevent Respiratory Syncytial Virus-associated Illness in Young Children.
Ruth A. Karron, Jessica E. Atwell, Elizabeth J. McFarland, Coleen K. Cunningham, Petronella Muresan
American Journal of Respiratory and Critical Care Medicine. 2021-03-01
13 citations
SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.
Evan J Anderson, John P DeVincenzo, Eric A F Simões, Leonard R Krilov, Michael L Forbes
American Journal of Perinatology. 2020-03-01
5 citations
Population Pharmacokinetics of Milrinone in Infants, Children, and Adolescents.
Christoph P. Hornik, Ram Yogev, Peter M. Mourani, Kevin M. Watt, Janice E. Sullivan
Journal of Clinical Pharmacology. 2019-07-17

Press Mentions

Effectiveness of Efavirenz-Based Antiretroviral Therapy for HIV-Infected ChildrenNovember 3rd, 2015
Treating Opportunistic Infections Among HIV-Exposed and Infected Children: Recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of AmericaFebruary 1st, 2005

Grant Support

Units For HIV/AIDS Clinical Trials NetworksNational Institute Of Allergy And Infectious Diseases2007–2012
Pactg P1038: High Dose Lopinavir/Ritonavir With Or Without Saquinavir In HIV PTSNational Center For Research Resources2006–2007
Pactg P1021: Emtricitabine In Combination With Efavirenz &Didanosine In ARTNational Center For Research Resources2006–2007
Pactg 1020-A: Protease Inhibitor (Bms 232632) In Combination Regimen In ARTNational Center For Research Resources2006–2007
Pediatric AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases1993–2006
Pharmacokinetics Of Antiretrovirals Following Gastrostomy Tube AdministrationNational Center For Research Resources2004
Pactg P1030: A Phase I/II Study Of Lopinavir/Ritonavir In HIV-1 Infected InfantsNational Center For Research Resources2004
Actg226--Oral Ganciclovir In HIV Infected Children With Asymptomatic CMVNational Center For Research Resources1998–1999
Actg--Pharmacokinetic And Tolerance Study Of Oral GanciclovirNational Center For Research Resources1997
Actg--Atovaquone /Azithromycin Compared To Trimethoprim-SulfamethoxazoleNational Center For Research Resources1997
Phase I Safety And Tolerance Study Of M-AtovaquoneNational Center For Research Resources1996
Pharmacokinetic And Tolerance Study Of Oral GanciclovirNational Center For Research Resources1996
Pediatric AIDS Clinical Trials GroupNational Institute Of Allergy And Infectious Diseases1988–1992

RamYogevMD

Dr. Yogev is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Press Mentions

Grant Support

Viewing the full profile is available to verified healthcare professionals only.